SCHEMBL3229983

SCHEMBL3229983

O=Cc1ccc(CCO)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
DPP4 P27487 1/20 0.35
CYP2A6 P11509 2/20 0.33
CYP2E1 P05181 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2B6 P20813 1/20 0.33
CYP2C19 P33261 1/20 0.33
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TSHR P16473 2/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16901837 0.88 ALDH1A1 (0.37) ALDH1A1ADRA1DADRA1AADRA1BDPP4
SCHEMBL29020313 0.87 ALDH1A1 (0.44) ALDH1A1ADRA1DADRA1AADRA1BDPP4
SCHEMBL8185448 0.83
SCHEMBL12664443 0.83 ALDH1A1 (0.41) ALDH1A1ADRA1DADRA1AADRA1BDPP4
SCHEMBL30762031 0.79 ALDH1A1 (0.39) ALDH1A1ADRA1DADRA1AADRA1BDPP4
SCHEMBL1418985 0.79 ALDH1A1 (0.47) ALDH1A1ADRA1DADRA1AADRA1BDPP4
SCHEMBL9794742 0.79 RPS6KB2 (0.43) ALDH1A1POLBMAPTKMT2ATSHR
SCHEMBL9013525 0.76 DPP4 (0.39) ALDH1A1DPP4CYP2A6CYP2E1CYP3A4
SCHEMBL10684074 0.76 ALDH1A1 (0.49) ALDH1A1ADRA1DADRA1AADRA1BMEN1
SCHEMBL16901815 0.76 ALDH1A1 (0.37) ALDH1A1ADRA1DADRA1AADRA1BDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022187693-A1 COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES UMBRA THERAPEUTICS INC. (US) 2022-09-09 WO disclosed
US-20200148702-A1 COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS DANA FARBER CANCER INST INC (US) 2020-05-14 US disclosed
WO-2010015792-A1 NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA-2 RECEPTORS ARGENTA DISCOVERY LIMITED (GB) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148702-A1 COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS BRPF3, EP300, BRD3 ALDH1A1 3670/4885ADRA1D 4744/4885ADRA1A 4504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.